Aeterna Zentaris Inc (AEZS)

$5.43

Market is closed - opens 7 PM, 24 Jul 2024

Performance

  • $5.39
    $5.44
    $5.43
    downward going graph

    0.74%

    Downside

    Day's Volatility :0.92%

    Upside

    0.18%

    downward going graph
  • $3.96
    $12.68
    $5.43
    downward going graph

    27.07%

    Downside

    52 Weeks Volatility :68.77%

    Upside

    57.18%

    downward going graph

Returns

PeriodAeterna Zentaris IncIndex (Russel 2000)
3 Months
-31.09%
0.0%
6 Months
-28.55%
0.0%
1 Year
-55.64%
0.0%
3 Years
-92.3%
-19.9%

Highlights

Market Capitalization
17.0M
Book Value
$10.68
Earnings Per Share (EPS)
-2.31
PEG Ratio
0.0
Wall Street Target Price
15.0
Profit Margin
0.0%
Operating Margin TTM
-152750.0%
Return On Assets TTM
-29.96%
Return On Equity TTM
-81.71%
Revenue TTM
2.4M
Revenue Per Share TTM
1.96
Quarterly Revenue Growth YOY
-99.8%
Gross Profit TTM
5.2M
EBITDA
-19.9M
Diluted Eps TTM
-2.31
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Aeterna Zentaris Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 176.24%

Current $5.43
Target $15.00

Company Financials

FY18Y/Y Change
Revenue
26.9M
↑ 2812.35%
Net Income
4.2M
↓ 124.93%
Net Profit Margin
15.58%
↑ 1835.3%
FY19Y/Y Change
Revenue
532.0K
↓ 98.02%
Net Income
-6.0M
↓ 244.3%
Net Profit Margin
-1.1K%
↓ 1151.29%
FY20Y/Y Change
Revenue
3.7M
↑ 586.47%
Net Income
-5.1M
↓ 15.29%
Net Profit Margin
-140.14%
↑ 995.57%
FY21Y/Y Change
Revenue
5.3M
↑ 44.03%
Net Income
-8.4M
↑ 63.5%
Net Profit Margin
-159.09%
↓ 18.95%
FY22Y/Y Change
Revenue
5.6M
↑ 7.22%
Net Income
-37.7M
↑ 350.16%
Net Profit Margin
-667.89%
↓ 508.8%
FY23Y/Y Change
Revenue
4.6M
↓ 18.79%
Net Income
-16.9M
↓ 55.25%
Net Profit Margin
-367.99%
↑ 299.9%
Q4 FY22Q/Q Change
Revenue
2.5M
↑ 33.6%
Net Income
-20.9M
↑ 570.05%
Net Profit Margin
-841.01%
↓ 673.32%
Q1 FY23Q/Q Change
Revenue
2.1M
↓ 14.37%
Net Income
-4.4M
↓ 79.13%
Net Profit Margin
-204.98%
↑ 636.03%
Q2 FY23Q/Q Change
Revenue
2.2M
↑ 5.55%
Net Income
-2.5M
↓ 42.27%
Net Profit Margin
-112.11%
↑ 92.87%
Q3 FY23Q/Q Change
Revenue
3.0K
↓ 99.87%
Net Income
-4.1M
↑ 64.61%
Net Profit Margin
-138.2K%
↓ 138054.56%
Q4 FY23Q/Q Change
Revenue
124.3K
↑ 4044.8%
Net Income
-5.8M
↑ 39.7%
Net Profit Margin
-4.7K%
↑ 133509.64%
Q1 FY24Q/Q Change
Revenue
2.0M
↑ 2130.74%
Net Income
-1.4M
↓ 67.36%
Net Profit Margin
-68.14%
↑ 4588.89%
FY18Y/Y Change
Total Assets
25.0M
↑ 12.69%
Total Liabilities
23.1M
↓ 7.5%
FY19Y/Y Change
Total Assets
20.0M
↓ 20.11%
Total Liabilities
22.4M
↓ 2.86%
FY20Y/Y Change
Total Assets
37.3M
↑ 86.56%
Total Liabilities
24.1M
↑ 7.23%
FY21Y/Y Change
Total Assets
80.1M
↑ 114.88%
Total Liabilities
27.1M
↑ 12.67%
FY22Y/Y Change
Total Assets
56.0M
↓ 30.06%
Total Liabilities
20.3M
↓ 25.32%
FY23Y/Y Change
Total Assets
36.8M
↓ 34.27%
Total Liabilities
18.7M
↓ 7.54%
Q4 FY22Q/Q Change
Total Assets
56.0M
↓ 15.88%
Total Liabilities
20.3M
↑ 17.81%
Q1 FY23Q/Q Change
Total Assets
51.3M
↓ 8.47%
Total Liabilities
20.1M
↓ 0.87%
Q2 FY23Q/Q Change
Total Assets
46.5M
↓ 9.36%
Total Liabilities
17.4M
↓ 13.3%
Q3 FY23Q/Q Change
Total Assets
42.5M
↓ 8.6%
Total Liabilities
16.2M
↓ 6.87%
Q4 FY23Q/Q Change
Total Assets
36.8M
↓ 13.32%
Total Liabilities
18.7M
↑ 15.52%
Q1 FY24Q/Q Change
Total Assets
21.7M
↓ 20.14%
Total Liabilities
2.5M
↓ 81.71%
FY18Y/Y Change
Operating Cash Flow
6.8M
↓ 129.79%
Investing Cash Flow
-35.0K
↓ 111.4%
Financing Cash Flow
3.9M
↓ 51.52%
FY19Y/Y Change
Operating Cash Flow
-10.7M
↓ 257.14%
Investing Cash Flow
50.0K
↓ 242.86%
Financing Cash Flow
3.9M
↑ 0.0%
FY20Y/Y Change
Operating Cash Flow
-4.1M
↓ 61.5%
Investing Cash Flow
56.0K
↑ 12.0%
Financing Cash Flow
20.5M
↑ 425.76%
FY21Y/Y Change
Operating Cash Flow
-8.6M
↑ 107.82%
Investing Cash Flow
-658.0K
↓ 1275.0%
Financing Cash Flow
51.0M
↑ 149.35%
Q4 FY22Q/Q Change
Operating Cash Flow
-3.4M
↓ 13.21%
Investing Cash Flow
-3.0K
↓ 40.0%
Financing Cash Flow
-17.0K
↓ 48.48%
Q1 FY23Q/Q Change
Operating Cash Flow
-4.1M
↑ 18.6%
Investing Cash Flow
-3.0K
↑ 0.0%
Financing Cash Flow
-38.0K
↑ 123.53%
Q2 FY23Q/Q Change
Operating Cash Flow
-4.3M
↑ 5.71%
Investing Cash Flow
-3.0K
↑ 0.0%
Financing Cash Flow
-42.0K
↑ 10.53%

Technicals Summary

Sell

Neutral

Buy

Aeterna Zentaris Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aeterna Zentaris Inc
Aeterna Zentaris Inc
20.67%
-28.55%
-55.64%
-92.3%
-97.76%
Moderna, Inc.
Moderna, Inc.
-11.5%
19.92%
-1.43%
-63.9%
737.94%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.78%
11.32%
45.17%
82.69%
236.57%
Novo Nordisk A/s
Novo Nordisk A/s
-6.33%
26.68%
64.47%
198.6%
438.18%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.24%
14.68%
37.33%
146.48%
182.87%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aeterna Zentaris Inc
Aeterna Zentaris Inc
NA
NA
0.0
0.0
-0.82
-0.3
NA
10.68
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.55
31.55
1.46
44.35
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.95
45.95
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.16
32.16
0.53
17.04
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aeterna Zentaris Inc
Aeterna Zentaris Inc
Buy
$17.0M
-97.76%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.9B
737.94%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.9B
236.57%
31.55
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.6B
438.18%
45.95
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.0B
182.87%
32.16
39.46%

Insights on Aeterna Zentaris Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 3.0K → 2.77M (in $), with an average increase of 96.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -5.79M → -1.89M (in $), with an average increase of 206.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 64.5% return, outperforming this stock by 120.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 193.7% return, outperforming this stock by 286.1%

Institutional Holdings

  • Morgan Stanley - Brokerage Accounts

    0.33%
  • Edmond de Rothschild Holding S.A.

    0.08%
  • JPMorgan Chase & Co

    0.02%
  • Royal Bank of Canada

    0.01%

Company Information

æterna zentaris inc. (tsx: aez, nasdaq: aezs) is a global biopharmaceutical company focused on endrocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. æterna zentaris inc. (tsx: aez, nasdaq: aezs) est une société biopharmaceutique internationale, spécialisée dans la découverte, le développement et la commercialisation de thérapies en endocrinologie et en oncologie.

Organization
Aeterna Zentaris Inc
Employees
0
CEO
Dr. Klaus Paulini Ph.D.
Industry
Health Technology

FAQs